Список проголосовавших за комментарий " Gapping up/down: ADBE +5%, TIF +4% and STLD +3% after earnings/guidance, TSLA +1% following offering, DF +2% after upgrade; SEAS -2% and NFLX -1% after analyst notes/comments<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>AVXS</strong> +11.3%, <strong>FATE</strong> +7.8%, <strong>VSLR</strong> +7.3%, <strong>OMER</strong> +6%, <strong>ADBE</strong> +5.2%, <strong>FF</strong> +4.9%, <strong>CATB</strong> +4.1%, <strong>TIF</strong> +3.5%</li><li><strong>AGRO</strong> +3.3%, <strong>MNKD</strong> +2.9%, <strong>STLD</strong> +2.7%, <strong>STNG</strong> +2.3%, <strong>CALA</strong> +1.1%, <strong>ONCS</strong> +0.8%, <strong>WLB</strong> +0.5%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>CLBS</strong> +47.5% (sells stake in PCT to Hitachi Chemical for $75 mln; also reported earnings)</li><li><strong>THLD</strong> +39.4% (will merge with Molecular Templates in an all-stock transaction)</li><li><strong>NSAT</strong> +14.9% (announces Privet Fund Management provided a non-binding letter of interest to acquire NSAT for $10.25/share — shares halted)</li></ul><p><strong>Select shipping related names showing strength</strong>:</p><ul><li><strong>ESEA</strong> +9.1%, <strong>TOPS</strong> +7.7%, <strong>DCIX</strong> +4.3%, <strong>DRYS</strong> +2.7%, <strong>STNG</strong> +2.3%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>GALE</strong> +21.1% (presents final analysis from the GALE-301 (E39) investigator-sponsored Phase 1/2a clinical trial)</li><li><strong>ABUS</strong> +8.8% (Licenses to Alexion Pharmaceuticals (ALXN) its proprietary lipid nanoparticle technology for exclusive use in one of Alexion's rare disease programs)</li><li><strong>FNJN</strong> +8.1% (Positive patent ruling)</li><li><strong>VRX</strong> +4.4% (ValueAct adds 3 mln shares, now holds 5.2% stake)</li><li><strong>GOOS</strong> +4% (Positive Jim Cramer mention)</li><li><strong>AUPH</strong> +2.3% (To present 48-week results from its AURION open-label study of voclosporin for the treatment of lupus nephritis at the International Congress on Systemic Lupus Erythematosus on March 27)</li><li><strong>AGRX</strong> +1.9% (Announces a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla; plans to resubmit its new drug application in the first half of 2017)</li><li><strong>NVDA</strong> +1% (continued strength)</li><li><strong>TSLA</strong> +1% (prices upsized 1.34 mln common stock offering at $262/share)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>FIVN</strong> +2.8% (upgraded to Overweight from Sector Weight at Pacific Crest)</li><li><strong>RBS</strong> +2.5% (upgraded to Buy from Reduce at Natixis)</li><li><strong>DF</strong> +2.3% (upgraded to Overweight from Neutral at JP Morgan)</li><li><strong>HIMX</strong> +1.8% (upgraded to Buy from Neutral at ROTH Capital)</li><li><strong>BCS</strong> +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)</li><li><strong>PUK</strong> +1.1% (upgraded to Neutral from Underweight at JP Morgan)</li><li><strong>BHP</strong> +1% (upgraded to Buy from Hold at Investec)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>STML</strong> -21.2%, <strong>CMLS</strong> -19.8%, <strong>EXA</strong> -11.6%, <strong>CAL</strong> -8.6%, <strong>CSBR</strong> -7.9%, <strong>GSVC</strong> -7.5%</li><li><strong>XONE</strong> -6.3%, <strong>VUZI</strong> -5.6%, <strong>BREW</strong> -5.5%, <strong>AFSI</strong> -5.1%, <strong>INNL</strong> -4.7%, <strong>BIOA</strong> -4.5%</li><li><strong>QBAK</strong> -3.2%, <strong>VRAY</strong> -3%, <strong>BDSI</strong> -2.5%, <strong>KINS</strong> -0.7%, <strong>LPLA</strong> -0.7%</li></ul><p><strong>M&A news</strong>: </p><ul><li><strong>RYN</strong> -3.5% (To acquire approx. 95,100 acres of high-quality industrial timberlands located in Florida, Georgia and South Carolina for an aggregate purchase price of approximately $217 mln; commences 5 mln share common stock offering), .</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>VRTV</strong> -8.2% (prices offering by selling shareholders of 1.8 mln shares of common stock at $54.85 per share)</li><li><strong>EDIT</strong> -7.8% (prices offering of 4 mln shares of common stock at $22.50 per share)</li><li><strong>NYMT</strong> -5.4% (Reduces quarterly dividend to $0.20/share from $0.24/share)</li><li><strong>AFSI</strong> -5.1% (To delay 10-K filing, plans to restate 2014 and 2015 results)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>SEAS</strong> -2.4% (downgraded to Sell from Neutral at Citigroup)</li><li><strong>BUFF</strong> -1.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley)</li><li><strong>NFLX</strong> -1.1% (attributed to cautious comments from analyst at M Science regarding subscriber metrics, also — initiated with a Outperform at Bernstein)</li><li><strong>GOLD</strong> -0.7% (downgraded to Hold from Buy at Deutsche Bank)</li></ul>"